文献速递系统性红斑狼疮

SLEDAI-2K糖皮质激素指数识别系统性红斑狼疮治疗应答

Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-07-27

基于多伦多狼疮诊所1995至2018年188例活动期且接受泼尼松≥5 mg/天的成人患者,比较SLEDAI-2K与SLEDAI-2KG以4分为界识别标准治疗应答的表现。SLEDAI-2KG在SLEDAI-2K应答者中识别出142例(97.9%)应答,并在SLEDAI-2K非应答者中额外识别11例(25.6%)应答,归因于其纳入糖皮质激素剂量变化。

要点

  • SLEDAI-2KG在SLEDAI-2K应答者中识别142/145例(97.9%)应答。
  • SLEDAI-2KG在43例SLEDAI-2K非应答者中额外识别11例(25.6%)应答。
  • SLEDAI-2KG较SLEDAI-2K增加糖皮质激素剂量这一变量,可能改变药物试验与观察性研究的应答率。

核心结论

  • SLEDAI-2KG在评估狼疮疾病活动度时纳入糖皮质激素剂量,可改变应答识别结果。

研究设计与样本

  • 分析多伦多大学狼疮诊所1995至2018年成人患者数据,纳入SLEDAI-2K≥6且泼尼松≥5 mg/天并有9个月随访者,以4分为界比较两指数。

主要发现

  • 188例中女性86.0%、白人47.9%;145例(77.1%)为应答者且SLEDAI-2K下降≥4。
  • SLEDAI-2KG在SLEDAI-2K应答者中识别142例(97.9%)应答。
  • SLEDAI-2KG在SLEDAI-2K非应答者(n=43)中额外识别11例(25.6%)应答。

关键数值与推荐

  • 应答判定采用SLEDAI-2K下降≥4分的 cutoff 点;活动期定义为SLEDAI-2K≥6,入组要求泼尼松≥5 mg/天。

临床怎么用

  • 在临床研究或观察性研究中评估狼疮应答时,可考虑用SLEDAI-2KG纳入激素剂量变化对应答率的影响。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the performance of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the SLEDAI-2K Glucocorticoids (SLEDAI-2KG) indices in identifying responders to standard of care therapy. METHODS: Data from adult patients seen between 1995 and 2018 at the University of Toronto Lupus Clinic were analyzed. Patients with active disease (SLEDAI-2K score ≥6) and receiving prednisone ≥5 mg/day, and with a follow-up visit at 9 months, were studied. Response to standard of care therapy at first follow-up visit was assessed using the SLEDAI-2K and SLEDAI-2KG. The performances of the SLEDAI-2K and SLEDAI-2KG were compared using a cutoff point of 4. RESULTS: In a cohort of 188, the majority of patients were female (86.0%) and White (47.9%). Of 188 patients, 145 (77.1%) were responders and had a decrease in SLEDAI-2K score of ≥4. The SLEDAI-2KG identified 142 (97.9%) responders among the SLEDAI-2K responders. More importantly, the SLEDAI-2KG identified 11 (25.6%) additional responders among SLEDAI-2K nonresponders (n = 43). This resulted from the ability of the SLEDAI-2KG to account for the decrease in glucocorticoids dose. CONCLUSION: The SLEDAI-2KG provides a novel concept for the assessment of lupus disease activity while accounting for glucocorticoids dosage to reflect on disease activity overall at a particular visit. The SLEDAI-2KG accounts for the disease activity for each descriptor while also accounting for the current glucocorticoids dosage. The SLEDAI-2KG adds 1 additional variable (glucocorticoids dosage) to the SLEDAI-2K, which could alter response rates in drug trials and observational studies.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Touma Z, Gladman DD, Zandy M, et al. Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. Arthritis Care Res (Hoboken). 2021. PMID: 32433815. doi:10.1002/acr.24261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。